MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) announced that it received approval from Health Canada's Pest Management Regulatory Agency (PMRA) to begin large-scale farmer trials via NexusBioAg's 2024 BioAdvantage Trials (BAT) Program to evaluate large-scale efficacy and commercial value potential.
The agriculture biotech company said the program will focus on MustGrow's TerraMG mustard-derived soil biopesticide technology for use in Canadian canola and pulse crop markets, which further diversifies and expands NexusBioAg's extensive portfolio of inoculants, micronutrients, nitrogen stabilizers and foliars for the Canadian agricultural market.
"We will collaborate with MustGrow to conduct large scale field trials throughout Western Canada and give agriculture innovators an opportunity to work with true agriculture innovation," NexusBioAg senior marketing manage Daniel Samphir said in a statement.
Combining the proficiencies of both companies in the agriculture market will help Canadian farmers benefit from innovative and sustainable farming solutions, according to the company.
MustGrow added that its sustainable farming technology has the potential to address the agronomic challenges of clubroot and aphanomyces diseases that are rapidly devastating canola and pulse crops.
MustGrow is an agriculture biotech company developing organic biocontrol, soil amendment and biofertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply and help farmers feed the world.
Contact Sean at sean@proactiveinvestors.com